Announcements Trials

Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Gastrointestinal Neoplasms 3 Esophageal Neoplasms 2 Stomach Neoplasms 1 Sarcoma 1 Prostatic Neoplasms 1 Peritoneal Neoplasms 1 Pelvic Neoplasms 1 Ovarian Neoplasms 1 Osteosarcoma 1 Lung Neoplasms 1 Head and Neck Neoplasms 1 Endometrial Neoplasms 1 Appendiceal Neoplasms 1

Interventions

pembrolizumab 45 Paclitaxel 42 Carboplatin 34 Bevacizumab 18 Specimen Handling 17 Letrozole 16 lenvatinib 13 Magnetic Resonance Spectroscopy 12 dostarlimab 11 Cisplatin 11 Biopsy 11 Taxes 10 olaparib 9 Fulvestrant 9 Doxorubicin 9 abemaciclib 8 Megestrol Acetate 8 Docetaxel 8 durvalumab 7 atezolizumab 7 Nivolumab 7 Gemcitabine 7 Blood Specimen Collection 7 palbociclib 6 Oxaliplatin 6 Observation 6 Fluorouracil 6 niraparib 5 Surveys and Questionnaires 5 Progestins 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Endometrial Neoplasms × Pafolacianine × 1 year × Clear all

NCT07278986 2025-12-12

CYTALUX ISS

Abramson Cancer Center at Penn Medicine

Phase EARLY_PHASE1 Recruiting

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡